健康元药业集团 关联交易管理制度 健康元药业集团股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范健康元药业集团股份有限公司（以下简称"公司"）关联交易 活动，保证公司与各关联方所发生关联交易的合法性、公允性、合理性，保障公 司、股东和债权人的合法权益，根据《中华人民共和国公司法》、《中华人民共 和国证券法》、《上海证券交易所股票上市规则》（以下简称"《股票上市规则》"）、 《上海证券交易所上市公司自律监管指引第5号——交易与关联交易》等法律法 规、规范性文件和《健康元药业集团股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，结合公司实际，制定本制度。 第二条 公司在确认和处理有关关联人之间关联关系与关联交易时，应遵循 并贯彻以下原则: (一) 诚实信用； (二) 关联交易应在真实公允的基础上进行； (三) 切实履行关联交易信息披露的有关规定； (四) 关联董事和关联股东在审议与之相关的关联交易的董事会或股东会上 应当回避表决，也不得代其他董事或股东行使表决权； (五) 公司董事会应当根据客观标准判断该关联交易是否对公司有利，必要 时聘请中介机构发表意见和报告。 第三条 公司在处理与关联人 ...

健康元药业集团 董事会议事规则 健康元药业集团股份有限公司 第五条 临时会议 董事会议事规则 第一条 宗旨 为了进一步规范健康元药业集团股份有限公司（以下简称"本公司"）董事 会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规 范运作和科学决策水平，根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司治理准则》《上海证券交易所股票上市规则》等相关法律、行政法 规、部门规章、规范性文件以及《健康元药业集团股份有限公司章程》（以下简 称"公司章程"）的规定，制订本规则。 第二条 董事会办公室 董事会下设董事会办公室，处理董事会日常事务。 董事会秘书或者证券事务代表兼任董事会办公室负责人。 第三条 定期会议 董事会每年至少召开两次会议，由董事长召集，于会议召开十日以前书面通 知全体董事。 第四条 定期会议的提案 在发出召开董事会定期会议的通知前，董事会办公室应当充分征求各董事的 意见，初步形成会议提案后交董事长拟定。 董事长在拟定提案前，应当视需要征求总裁和其他高级管理人员的意见。 有下列情形之一的，董事会应当召开临时会议： 1 （一）代表十分之一以上表决权的股东提议时； （二）三分 ...

健康元药业集团 关于职工代表大会选举职工董事的公告 特此公告。 健康元药业集团股份有限公司 二〇二五年十一月十五日 1 / 2 证券代码：600380 证券简称： 健康元 公告编号：临 2025-076 健康元药业集团股份有限公司 关于职工代表大会选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）于 2025 年 11 月 14 日召开 2025 年第二次临时股东大会，审议并通过《关于取消监事会、变更注册资本及修订< 公司章程>部分条款的议案》。根据新修订的《公司章程》，公司董事会由十名董事 组成，包括职工董事一名。 为保证公司董事会的合规运作，公司于同日召开 2025 年第一次职工代表大会， 审议并通过《关于选举公司第九届董事会职工代表董事的议案》，选举杨颖女士为公 司第九届董事会职工董事（简历详见附件）。杨颖女士将与其他九名现任董事共同组 成公司第九届董事会，任期自本次职工代表大会审议通过之日起至公司第九届董事会 任期届满之日止。 杨颖女士符合《公司法》等相关 ...

2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 健康元药业集团 2025 年第二次临时股东会决议公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-075 健康元药业集团股份有限公司 一、会议召开和出席情况 1、股东会召开的时间：2025 年 11 月 14 日 2、股东会召开的地点：深圳市南山区高新区北区朗山路 17 号健康元药业集团 大厦二号会议室 3、出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | （1）出席会议的股东和代理人人数 | 502 | | --- | --- | | （2）出席会议的股东所持有表决权的股份总数（股） | 926,416,816 | | （3）出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 50.6389 | 4、表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，经半数以上董事推举，董事林楠棋先生主持本次 会议 ...

北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 2025 年第二次临时股东会的 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 ——————————————————————————— ——————————————————————————— 北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 2025 年第二次临时股东会的法律意见 北京德恒（深圳）律师事务所 关于健康元药业集团股份有限公司 2025 年第二次临时股东会的 法律意见 德恒 06F20240039-026 号 致：健康元药业集团股份有限公司 健康元药业集团股份有限公司（以下简称"公司"）2025 年第二次临时股 东会（以下简称"本次会议"）于 2025 年 11 月 14 日（星期五）召开。北京德 恒（深圳）律师事务所（以下简称"德恒"或"本所"）受公司委托，指派皇甫 天致律师、黄俐娜律师（以下简称"本所律师"）出席了本次会议。根据《中华 人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》 （以下简称 ...

Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]

Core Viewpoint - The company, Joincare Pharmaceutical Group Industry Co., Ltd., has announced the convening of its second extraordinary general meeting of shareholders for 2025, scheduled for November 14, 2025, to discuss specific proposals [2][3]. Group 1: Meeting Details - The second extraordinary general meeting of shareholders will be held on November 14, 2025, at 15:00 in the conference room of Joincare Pharmaceutical Group Building, located at No. 17, Langshan Road, High-tech Zone, Nanshan District, Shenzhen [3][11]. - The meeting will utilize a combination of on-site and online voting methods, with the online voting system provided by the Shanghai Stock Exchange [3][4]. - The online voting will be available on the day of the meeting from 9:15 to 15:00, with specific trading time slots for voting through the trading system [4]. Group 2: Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system, either via the trading system or the internet voting platform [7][8]. - Special resolutions require approval from more than two-thirds of the voting rights held by attending shareholders [7]. - The company will provide a reminder service for shareholders to ensure participation, utilizing smart SMS notifications based on the shareholder registry [8]. Group 3: Attendance and Registration - Shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the registration date are entitled to attend the meeting [11]. - Registration for the meeting can be done in person or via fax or mail, with specific deadlines outlined for both methods [14][15]. - The meeting will last half a day, and attendees are responsible for their own accommodation and travel expenses [18].

健康元药业集团 关于召开 2025 年第二次临时股东会的提示性公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-074 健康元药业集团股份有限公司 1、股东会类型和届次 2025年第二次临时股东会 2、股东会召集人：董事会 3、投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 4、现场会议召开的日期、时间和地点 关于召开2025年第二次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●股东会召开日期：2025年11月14日 ●本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 ●公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供的股东会提 醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股东名册主动提 醒股东参会投票，向每一位投资者主动推送股东会参会邀请、议案情况等信息。 一、召开会议的基本情况 召开的日期时间：2025 年 11 月 14 日 15 点 00 分 召开地点：深圳市南山区高新区北区朗山路 17 ...

Core Viewpoint - Health元's stock price has shown a slight increase of 2.02% on October 31, reaching 12.12 yuan per share, with a total market capitalization of 22.173 billion yuan [1] Financial Performance - For the period from January to September 2025, Health元 reported operating revenue of 11.478 billion yuan, a year-on-year decrease of 3.54%, and a net profit attributable to shareholders of 1.091 billion yuan, down 1.83% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 3.979 billion yuan, with 1.04 billion yuan distributed over the past three years [3] Stock Market Activity - As of October 31, Health元's stock has increased by 9.49% year-to-date, with a slight increase of 0.17% over the last five trading days, but a decline of 1.94% over the last 20 days and 4.57% over the last 60 days [1] - The stock has seen a net inflow of 1.5702 million yuan from major funds, with significant buying and selling activity recorded [1] Shareholder Information - As of September 30, 2025, the number of shareholders for Health元 increased to 81,400, a rise of 6.79%, while the average circulating shares per person decreased by 6.36% to 22,465 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 500 ETF, with notable changes in their holdings [3]

Core Viewpoint - Health元 is transitioning from a "research investment phase" to a "value realization phase" in its innovative drug development, with significant progress in multiple core products, particularly the flu treatment drug, Marpapsavir, which is expected to be launched in 2024 [2][5] Financial Performance - In the first three quarters of 2025, Health元 achieved operating revenue of 11.478 billion yuan and a net profit of 1.091 billion yuan, with basic earnings per share of 0.6 yuan [1] Innovation Pipeline - The company has a robust innovation pipeline with over 20 first-class innovative drugs, 10 of which have entered critical phases beyond Phase II, indicating a well-structured pipeline matrix [3] - Marpapsavir, a novel drug for treating influenza, has completed Phase III clinical trials and is set to submit for market approval in August 2024, showcasing its unique advantages in rapid efficacy and single-dose administration [2][3] R&D System - Health元 has established a comprehensive R&D system focusing on respiratory, digestive, mental health, and assisted reproduction fields, creating a closed-loop process from early target exploration to clinical development and commercialization [3] - The company has increased R&D investment by 15% year-on-year in the first half of 2025, emphasizing clinical advancement of innovative drugs and core technology upgrades [3] Sustainable Development - The company maintains a healthy cash flow supported by stable contributions from mature businesses, allowing for continued investment in R&D while ensuring financial health [4] - Since 2020, Health元 has completed a share repurchase plan totaling 3.2 billion yuan, with a dividend payout of 0.20 yuan per share for the 2024 fiscal year, reflecting a commitment to shareholder returns [4] Future Outlook - Health元 aims to accelerate the market launch of core products like Marpapsavir and deepen its comprehensive R&D layout, reinforcing its technological advantages in key therapeutic areas [5]